Biologics in the treatment of systemic lupus erythematosus : Current Opinion in Rheumatology
Biologics in the treatment of systemic lupus erythematosus : Current Opinion in Rheumatology …

BACKGROUND: Belimumab, a monoclonal antibody that inhibits B-lymphocyte stimulating
protein, was the first biologic agent approved for, and the first drug approved in 55 years for …

Systemic lupus erythematosus (SLE) is a chronic multisystem disease in which various cell
types and immunological pathways are dysregulated. Current therapies for SLE are based …

Systemic lupus erythematosus (SLE) is a complex autoimmune disease with substantial
clinical heterogeneity. Current treatments for SLE are effective at reducing morbidity and …

A 20-year-old woman with SLE presents with disease flares and receives belimumab, a
monoclonal antibody that binds to B-cell activating factor, inhibiting B-cell stimulation …

Given their pivotal role in autoantibody production, B-cells have become an attractive
therapeutic target in systemic lupus erythematosus (SLE). Belimumab, a fully human …

Objective: To investigate the effectiveness and safety of belimumab in patients with active
systemic lupus erythematosus (SLE) in a real-life setting. Methods: All SLE patients treated …

Introduction: Systemic lupus erythematosus (SLE) is a multi-systemic disease characterized
by an unpredictable disease course and periods of remission and flare, leading to organ …

Given the centrality of B cells to systemic lupus erythematosus (SLE), it stands to reason that
a candidate therapeutic agent that targets B cells could be efficacious. Both rituximab, a …

Objective To investigate the long‐term safety and efficacy of intravenous (IV) belimumab
plus standard of care (SOC) therapy for systemic lupus erythematosus (SLE) in patients with …